ArticleExperimental hematology2019

BCR-ABL1 tyrosine kinase inhibitor K0706 exhibits preclinical activity in Philadelphia chromosome-positive leukemia.

Orlando Antelope et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.